AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17416150 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutter
Number of subjects: 36
Study 17416150 — intervention group
Group type: EXPERIMENTAL
Intervention: ACBT
Number of subjects: 36
Study 15601349 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 4 microg x kg(‐1)
Number of subjects: 60
Study 15601349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 11377651 — intervention group
Group type: EXPERIMENTAL
Intervention: Local activation of low-dose ifosfamide using encapsulated genetically modified allogeneic cells delivered by supraselective angiography
Number of subjects: 14
Study 11377651 — intervention group
Group type: COMPARATOR
Intervention: Historic controls (not specified in detail)
Number of subjects: 14
Study 9517370 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil, 600 mg twice daily
Number of subjects: 0
Study 9517370 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin, 40 mg daily
Number of subjects: 0
Study 8278467 — intervention group
Group type: EXPERIMENTAL
Intervention: Siltex textured inflatable implant
Number of subjects: 56
Study 8278467 — intervention group
Group type: COMPARATOR
Intervention: Smooth inflatable implant
Number of subjects: 56
Study 8278467 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone-iodine irrigation
Number of subjects: 56
Study 8278467 — intervention group
Group type: COMPARATOR
Intervention: Saline irrigation
Number of subjects: 56
Study 2662695 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (3 g/day)
Number of subjects: 8
Study 2662695 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 4581246 — intervention group
Group type: EXPERIMENTAL
Intervention: Benapryzine
Number of subjects: 0
Study 31765030 — intervention group
Group type: EXPERIMENTAL
Intervention: nCPAP
Number of subjects: 93
Study 31765030 — intervention group
Group type: COMPARATOR
Intervention: BiPAP
Number of subjects: 93
Study 29961442 — intervention group
Group type: COMPARATOR
Intervention: Postal intervention (n=339)
Number of subjects: 1023
Study 29961442 — intervention group
Group type: COMPARATOR
Intervention: Nurse support (n=346)
Number of subjects: 1023
Study 29961442 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=338)
Number of subjects: 1023
Study 29961442 — intervention group
Group type: COMPARATOR
Intervention: Nurse support plus postal (n=346)
Number of subjects: 1023
Study 27429374 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose group (3 mg/m verteporfin, 83 seconds laser light)
Number of subjects: 40
Study 27429374 — intervention group
Group type: COMPARATOR
Intervention: Half-fluence group (6 mg/m verteporfin, 42 seconds laser light)
Number of subjects: 40
Study 27429374 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 26814085 — intervention group
Group type: EXPERIMENTAL
Intervention: NBI-assisted holmium laser resection (NBI-HoLRBt)
Number of subjects: 178
Study 26814085 — intervention group
Group type: COMPARATOR
Intervention: White light imaging assisted transurethral resection (WLI-TURBt)
Number of subjects: 178
Study 24363547 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole Prophylactic Treatment (CPT)
Number of subjects: 1236
Study 21910334 — intervention group
Group type: EXPERIMENTAL
Intervention: Tangshen Recipe (TR)
Number of subjects: 64
Study 21910334 — intervention group
Group type: EXPERIMENTAL
Intervention: Western medicine treatment (insulin and anti-diabetic drugs)
Number of subjects: 64
Study 21910334 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 64
Study 18452406 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoral appliance simulating occlusal conditions of shortened dental arches
Number of subjects: 13
Study 18452406 — intervention group
Group type: COMPARATOR
Intervention: No intraoral appliance (control)
Number of subjects: 13
Study 16541242 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan depletion (TD)
Number of subjects: 18
Study 16541242 — intervention group
Group type: COMPARATOR
Intervention: Control drink
Number of subjects: 18
Study 12671470 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide 2%
Number of subjects: 28
Study 12671470 — intervention group
Group type: COMPARATOR
Intervention: Placebo (tear-replacement drops)
Number of subjects: 28
Study 10871561 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat, low-fiber diet
Number of subjects: 22
Study 10871561 — intervention group
Group type: COMPARATOR
Intervention: Low-fat, high-fiber diet
Number of subjects: 22
Study 8997964 — intervention group
Group type: EXPERIMENTAL
Intervention: Staff education program based on the ENA Core Curriculum
Number of subjects: 20
Study 8997964 — intervention group
Group type: COMPARATOR
Intervention: Comparison group of registered nurses who did not attend the classes
Number of subjects: 20
Study 1361240 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine treatment
Number of subjects: 35
Study 6422900 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-hydroxytryptophan (5-HTP), 200 mg orally
Number of subjects: 0
Study 6422900 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate or monoamine oxidase (MAO) inhibitors
Number of subjects: 0
Study 6422900 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants (TCA) and second-generation antidepressants
Number of subjects: 0
Study 30544237 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning
Number of subjects: 124
Study 30544237 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 124
Study 29346378 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Clinic
Number of subjects: 195
Study 29346378 — intervention group
Group type: COMPARATOR
Intervention: Standard Clinic
Number of subjects: 195
Study 27641088 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 20
Study 27641088 — intervention group
Group type: COMPARATOR
Intervention: Palpation
Number of subjects: 20
Study 25286703 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided facet joint injection
Number of subjects: 20
Study 25286703 — intervention group
Group type: COMPARATOR
Intervention: Blindly administered facet joint block
Number of subjects: 20
Study 22811444 — intervention group
Group type: EXPERIMENTAL
Intervention: Dark chocolate (85% cocoa, 0.55 g/kg body wt)
Number of subjects: 22
Study 22811444 — intervention group
Group type: COMPARATOR
Intervention: White chocolate (control)
Number of subjects: 22
Study 22811444 — intervention group
Group type: EXPERIMENTAL
Intervention: Dark chocolate
Number of subjects: 22
Study 22811444 — intervention group
Group type: EXPERIMENTAL
Intervention: Dark chocolate and white chocolate
Number of subjects: 22
Study 20600400 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablets containing 20% (w/w) HPMC
Number of subjects: 6
Study 20600400 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablets containing 40% (w/w) HPMC
Number of subjects: 6
Study 20600400 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablets with lower concentration of HPMC and higher lactose concentration
Number of subjects: 6
Study 17646513 — intervention group
Group type: EXPERIMENTAL
Intervention: ropivacaine 0.05% with fentanyl 4 mug/mL and droperidol 25 microg/mL
Number of subjects: 312
Study 17646513 — intervention group
Group type: EXPERIMENTAL
Intervention: ropivacaine 0.075% with fentanyl 4 mug/mL and droperidol 25 microg/mL
Number of subjects: 312
Study 17646513 — intervention group
Group type: EXPERIMENTAL
Intervention: ropivacaine 0.1% with fentanyl 4 mug/mL and droperidol 25 microg/mL
Number of subjects: 312
Study 16286872 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg.kg(‐1) body mass)
Number of subjects: 9
Study 12670087 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg minocycline hydrochloride (Arestin) administered at baseline, three and six months
Number of subjects: 271
Study 12670087 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP)
Number of subjects: 271
Study 9619131 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to happy facial expressions
Number of subjects: 0
Study 9619131 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to angry facial expressions
Number of subjects: 0
Study 7654482 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5-10 mg once a day for 2 months
Number of subjects: 21
Study 2486962 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective appendectomy during cesarean section
Number of subjects: 90
Study 2486962 — intervention group
Group type: COMPARATOR
Intervention: Control group (cesarean section without appendectomy)
Number of subjects: 90
Study 798591 — intervention group
Group type: EXPERIMENTAL
Intervention: Halofenate
Number of subjects: 23
Study 798591 — intervention group
Group type: COMPARATOR
Intervention: Probenecid
Number of subjects: 23
Study 798591 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 6965977 — intervention group
Group type: EXPERIMENTAL
Intervention: Staphylococcus aureus adherence in patients with acute respiratory illness and volunteers infected with influenza virus
Number of subjects: 0
Study 6965977 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemophilus influenzae adherence in volunteers experimentally infected with influenza virus
Number of subjects: 0
Study 6965977 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptococcus pneumoniae type I adherence in volunteers experimentally infected with influenza virus
Number of subjects: 0
Study 31684867 — intervention group
Group type: EXPERIMENTAL
Intervention: IV lidocaine bolus 1.5 mg/kg at induction followed by an infusion (1.5 mg/kg/h)
Number of subjects: 90
Study 31684867 — intervention group
Group type: COMPARATOR
Intervention: IV esmolol bolus 0.5 mg/kg at induction followed by an infusion (5-15 μg/kg/min)
Number of subjects: 90
Study 31684867 — intervention group
Group type: EXPERIMENTAL
Intervention: IV lidocaine
Number of subjects: 90
Study 31684867 — intervention group
Group type: COMPARATOR
Intervention: IV esmolol
Number of subjects: 90
Study 29608789 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted Respecting Choices ACP program
Number of subjects: 201
Study 29608789 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 201
Study 26679480 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide respules via mucosal atomization device (MAD) twice daily
Number of subjects: 32
Study 26679480 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide respules instilled via vertex-to-floor (VF) position twice daily
Number of subjects: 32
Study 26679480 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone nasal spray twice daily
Number of subjects: 32
Study 25496532 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaire for assessing headache burden
Number of subjects: 1202
Study 23103035 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term PM(2.5) exposure (3 μg/m(3) increase)
Number of subjects: 3040
Study 23103035 — intervention group
Group type: COMPARATOR
Intervention: Short-term PM(2.5) exposure (12 μg/m(3) daily increase)
Number of subjects: 3040
Study 19762075 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal membrane oxygenation (ECMO)
Number of subjects: 180
Study 19762075 — intervention group
Group type: COMPARATOR
Intervention: Conventional management
Number of subjects: 180
Study 17496489 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine, 20 mg three times daily for 12 weeks
Number of subjects: 66
Study 17496489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 17496489 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine
Number of subjects: 66
Study 15648728 — intervention group
Group type: EXPERIMENTAL
Intervention: Straight-ahead movements
Number of subjects: 2
Study 15648728 — intervention group
Group type: EXPERIMENTAL
Intervention: Angled movements
Number of subjects: 2
Study 15648728 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinematic analysis
Number of subjects: 2
Study 15648728 — intervention group
Group type: EXPERIMENTAL
Intervention: Planning and control processes
Number of subjects: 2
Study 11977538 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary guidance and ingestion of aged garlic extract (AGE) capsules
Number of subjects: 100
Study 11977538 — intervention group
Group type: COMPARATOR
Intervention: Dietary guidance and non‐function capsules
Number of subjects: 100
Study 9846676 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal oestrogens 50 microg, 2 patches/week for 3 weeks per month, plus acetate nomegestrolo per os 5 mg/die for 12 days per cycle (Group A)
Number of subjects: 44
Study 9846676 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg/die (Group B)
Number of subjects: 44
Study 9846676 — intervention group
Group type: COMPARATOR
Intervention: No medication (Control Group C)
Number of subjects: 44
Study 8137201 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy and radiation therapy (CRT) - 20 Gy and two courses of 5-FU and cisplatin
Number of subjects: 86
Study 8137201 — intervention group
Group type: COMPARATOR
Intervention: Surgery (non-CRT)
Number of subjects: 86
Study 8137201 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (CRT and non-CRT)
Number of subjects: 86
Study 2589432 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamicel dilators
Number of subjects: 51
Study 2589432 — intervention group
Group type: COMPARATOR
Intervention: Dilapan dilators
Number of subjects: 51
Study 1262709 — intervention group
Group type: EXPERIMENTAL
Intervention: Freshly harvested vaccine (3 x 10(10)‐10(11) organisms/dose)
Number of subjects: 179
Study 1262709 — intervention group
Group type: EXPERIMENTAL
Intervention: Lyophilized vaccine
Number of subjects: 179
Study 1262709 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh vaccine
Number of subjects: 179
Study 1262709 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified treatment)
Number of subjects: 179
Study 31825893 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation program with PENS
Number of subjects: 16
Study 31825893 — intervention group
Group type: COMPARATOR
Intervention: Sham group (control)
Number of subjects: 16
Study 31169793 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound (via cloud‐based software measuring pixilation intensity)
Number of subjects: 30
Study 31169793 — intervention group
Group type: EXPERIMENTAL
Intervention: HIGH carbohydrate intake (8 g·kg body mass)
Number of subjects: 30
Study 31169793 — intervention group
Group type: COMPARATOR
Intervention: LOW carbohydrate intake (3 g·kg body mass)
Number of subjects: 30
Study 28193568 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 222
Study 28193568 — intervention group
Group type: COMPARATOR
Intervention: Best Available Therapy (BAT)
Number of subjects: 222
Study 25815420 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 683
Study 25815420 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 683
Study 25815420 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 683
Study 23446963 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified food supplement (SG)
Number of subjects: 0
Study 23446963 — intervention group
Group type: COMPARATOR
Intervention: No food supplement (NSG)
Number of subjects: 0
Study 21693443 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyalograft‐3D autograft followed by Laserskin autograft after 2 weeks (treatment group)
Number of subjects: 180
Study 21693443 — intervention group
Group type: COMPARATOR
Intervention: Nonadherent paraffin gauze (control group)
Number of subjects: 180
Study 18952009 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical l-NAME (NO synthase inhibitor)
Number of subjects: 12
Study 18952009 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation
Number of subjects: 12
Study 18952009 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 12
Study 17227571 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50-100 mg daily)
Number of subjects: 16
Study 17227571 — intervention group
Group type: COMPARATOR
Intervention: Carvedilol (12.5-25 mg)
Number of subjects: 16
Study 16083171 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ultrasound therapy with intensity of 0.5 W/cm2 applied to the palmar carpal tunnel for 10 minutes, 5 days a week for 4 weeks.
Number of subjects: 18
Study 16083171 — intervention group
Group type: COMPARATOR
Intervention: Sham ultrasound and Diclofenac 75 mg/day in divided doses.
Number of subjects: 18
Study 11063786 — intervention group
Group type: EXPERIMENTAL
Intervention: SES+SFT
Number of subjects: 30
Study 11063786 — intervention group
Group type: COMPARATOR
Intervention: SES
Number of subjects: 30
Study 9362823 — intervention group
Group type: EXPERIMENTAL
Intervention: Managing Aggressive Behavior program
Number of subjects: 0
Study 9362823 — intervention group
Group type: COMPARATOR
Intervention: Control group (did not attend the workshop)
Number of subjects: 0
Study 1545745 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational campaign for hospital staff and patients, including a booklet and video; duration not specified.
Number of subjects: 214
Study 1545745 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned but implied as those not exposed to the educational campaign).
Number of subjects: 214
Study 2418304 — intervention group
Group type: EXPERIMENTAL
Intervention: HOE 498 (2.5 mg)
Number of subjects: 0
Study 2418304 — intervention group
Group type: EXPERIMENTAL
Intervention: HOE 498 (5 mg)
Number of subjects: 0
Study 2418304 — intervention group
Group type: EXPERIMENTAL
Intervention: HOE 498 (10 mg)
Number of subjects: 0
Study 2418304 — intervention group
Group type: EXPERIMENTAL
Intervention: HOE 498 (20 mg)
Number of subjects: 0
Study 2418304 — intervention group
Group type: EXPERIMENTAL
Intervention: HOE 498 (various doses)
Number of subjects: 0
Study 2418304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31440980 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 1287
Study 31440980 — intervention group
Group type: COMPARATOR
Intervention: Ipilimumab
Number of subjects: 1287
Study 28094479 — intervention group
Group type: EXPERIMENTAL
Intervention: Retromolar direct laryngoscopy using Miller blade #4
Number of subjects: 100
Study 28094479 — intervention group
Group type: COMPARATOR
Intervention: Conventional direct laryngoscopy using Macintosh blade #3
Number of subjects: 100
Study 28094479 — intervention group
Group type: EXPERIMENTAL
Intervention: BURP maneuver
Number of subjects: 100
Study 25636013 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual distraction (Group A)
Number of subjects: 180
Study 25636013 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual distraction (Group B)
Number of subjects: 180
Study 25636013 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Group C)
Number of subjects: 180
Study 25636013 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual distraction (Group A) and Audiovisual distraction (Group B)
Number of subjects: 180
Study 22824921 — intervention group
Group type: EXPERIMENTAL
Intervention: propofol/fentanyl/dexmedetomidine (PFD)
Number of subjects: 54
Study 22824921 — intervention group
Group type: COMPARATOR
Intervention: propofol/fentanyl/placebo-saline (PFS)
Number of subjects: 54
Study 21448918 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 70 mg plus vitamin D(3) 2800 IU (ALN + D)
Number of subjects: 56
Study 21448918 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 18296901 — intervention group
Group type: EXPERIMENTAL
Intervention: Neolus (Ns)
Number of subjects: 312
Study 18296901 — intervention group
Group type: COMPARATOR
Intervention: Yale Spinal (YS)
Number of subjects: 312
Study 16813472 — intervention group
Group type: EXPERIMENTAL
Intervention: Brisk walking combined with moderate resistance training
Number of subjects: 134
Study 16813472 — intervention group
Group type: COMPARATOR
Intervention: Continuous walking
Number of subjects: 134
Study 16813472 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractionated walking (2 daily sessions)
Number of subjects: 134
Study 12944249 — intervention group
Group type: EXPERIMENTAL
Intervention: Dark chocolate (100 g)
Number of subjects: 30
Study 12944249 — intervention group
Group type: COMPARATOR
Intervention: White chocolate (100 g)
Number of subjects: 30
Study 12944249 — intervention group
Group type: COMPARATOR
Intervention: Milk chocolate (100 g)
Number of subjects: 30
Study 10468691 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (100 microg bolus)
Number of subjects: 24
Study 10468691 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 8735062 — intervention group
Group type: EXPERIMENTAL
Intervention: Recognition of depression by physicians
Number of subjects: 508
Study 8735062 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated BDI scores
Number of subjects: 508
Study 8735062 — intervention group
Group type: EXPERIMENTAL
Intervention: Failure to recognize depression
Number of subjects: 508
Study 1678316 — intervention group
Group type: EXPERIMENTAL
Intervention: Bopindolol (B) 2 mg once daily after initial 1 mg for 4 weeks
Number of subjects: 31
Study 1678316 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem (D) 240 mg in 4 divided doses after initial 120 mg
Number of subjects: 31
Study 7142984 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Group received a demonstration of physical and behavioral characteristics of their own infants resulting in a doubling of the usual time for interaction during the first two days.
Number of subjects: 48
Study 7142984 — intervention group
Group type: COMPARATOR
Intervention: Hospital Group spent the same amount of time viewing a prepared videotape of the same characteristics of a newborn infant who was not theirs.
Number of subjects: 48
Study 7142984 — intervention group
Group type: COMPARATOR
Intervention: Office Control Group, without experimental intervention.
Number of subjects: 48
Study 30362819 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (8 weeks, 3 sessions/week)
Number of subjects: 28
Study 27690742 — intervention group
Group type: EXPERIMENTAL
Intervention: CogState
Number of subjects: 272
Study 27690742 — intervention group
Group type: EXPERIMENTAL
Intervention: CNS‐VS
Number of subjects: 272
Study 27690742 — intervention group
Group type: COMPARATOR
Intervention: ANAM4
Number of subjects: 272
Study 27690742 — intervention group
Group type: COMPARATOR
Intervention: ImPACT
Number of subjects: 272